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Oligodendrocytes make myelin and support axons metabolically with lactate. However, it is 
unknown how glucose utilization and glycolysis are adapted to the different axonal energy 
demands. Spiking axons release glutamate and oligodendrocytes express NMDA receptors 
of unknown function. Here we show that the stimulation of oligodendroglial NMDA 
receptors mobilizes glucose transporter GLUT1, leading to its incorporation into the 
myelin compartment in vivo. When myelinated optic nerves from conditional NMDA 
receptor mutants are challenged with transient oxygen-glucose deprivation, they show a 
reduced functional recovery when returned to oxygen-glucose, but are indistinguishable 
from wildtype when provided with oxygen-lactate. Moreover, the functional integrity of 
isolated optic nerves, which are electrically silent, is extended by preincubation with 
NMDA and shortened by NMDA receptor blockers. This reveals a novel aspect of neuronal 
energy metabolism, in which activity-dependent glutamate release enhances 
oligodendroglial glucose uptake and glycolytic support of fast spiking axons. 
 
Introduction 
Oligodendrocytes, best known for making myelin (Emery, 2010; Nave and Werner, 2014), also 
support the survival of myelinated axons (Griffiths et al., 1998; Kassmann et al., 2007; Lappe-
Siefke et al., 2003). Myelin is assembled as a spiral extension of oligodendroglial cell 
membrane, which requires vesicular transport of membrane material through non-compacted 
cytosolic channels to the growing tip (Snaidero et al., 2014). In mature myelination, a system of 
nanometer-wide 'myelinic channels' is left behind, the dynamics and dimensions of which were 
only appreciated with the application of high-pressure freezing electron microscopy (Snaidero et 
al., 2014).  
Recently, the identification of metabolic coupling between oligodendrocytes and the axonal 
compartment, with glycolytic oligodendrocytes providing lactate to axons for aerobic ATP 
production (Fünfschilling et al., 2012; Lee et al., 2012), has introduced a new paradigm for the 
interaction of axons and their associated glial cells. However, the concept of glycolytic support 
by oligodendrocytes (Morrison et al., 2013; Saab et al., 2013) raises the question how glucose 
utilization is quantitatively regulated. Since the average spike count rate is the key determinant 
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of axonal ATP consumption, oligodendrocytes need to 'know' the spiking activity of myelinated 
axons, which can differ greatly in vivo (Barry, 2015; Perge et al., 2012). The constitutive 
overproduction of lactate would result in lactic acidosis, detrimental for white matter function. A 
plausible preventive mechanism would be that oligodendrocytes 'learn' their association with fast 
spiking axons to adapt their own energy metabolism.  
Like unmyelinated axons (Kukley et al., 2007; Wake et al., 2011; Ziskin et al., 2007) also 
myelinated axons release glutamate upon spiking which induces calcium elevations in myelin 
(Micu et al., 2015). Oligodendrocytes could take trace amounts of glutamate as a proxy for 
axonal spiking activity and energy needs. Indeed, periaxonal spaces underneath myelin are 
narrow (<50 nm) and glutamate could reach high local concentrations (Stys, 2011).  
Oligodendrocytes express different glutamate receptors, including NMDA receptors of unknown 
function (Karadottir et al., 2005; Micu et al., 2006; Salter and Fern, 2005). A role for NMDA 
receptor signalling in oligodendrocyte differentiation and promoting myelination has been 
suggested, based on in vitro observations (Li et al., 2013; Lundgaard et al., 2013), which is 
compatible with neuronal activity stimulating OPC proliferation and myelination in vivo (Gibson 
et al., 2014; Liu et al., 2012). Recently, axonal activity was shown to induce NMDA receptor-
mediated calcium increases in myelin, indicating that adult oligodendrocytes have functional 
NMDA receptors (Micu et al., 2015). However, conditional mouse mutants lacking this receptor 
from OPC reveal no major abnormality (De Biase et al., 2011; Guo et al., 2012).  
NR1 is the obligate subunit of tetrameric NMDA receptors and expression of its gene (Grin1) is 
higher in OPC than in mature oligodendrocytes (Zhang et al., 2014), but remains detectable 
throughout adult life (this study). Here, we tested the hypothesis that NMDA receptor signalling 
to oligodendrocytes is the missing link in coupling axonal activity and ATP consumption to 
oligodendroglial glucose utilization and lactate supply.  
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RESULTS 
NMDA receptor activation triggers GLUT1 surface expression and enhances glucose 
import in cultured oligodendrocytes 
Oligodendroglial GLUT1 was localized to intracellular compartments and primary processes, but 
only weakly to secondary and tertiary processes, and immature myelin membranes (Figure 1A, 
top). Cultured neurons mobilize glucose transporter GLUT3 in response to glutamate (Ferreira et 
al., 2011). We therefore asked whether GLUT1, the predominant transporter of oligodendrocytes 
and astrocytes (Zhang et al., 2014), behaves similarly.  
Remarkably, treatment with NMDA triggered GLUT1 redistribution in oligodendrocytes within 
30 min, leading to apparent surface expression (Figure 1A, middle) that was efficiently blocked 
by D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5) (Figure 1A, bottom; Figure 1C). In 
contrast, monocarboxylate transporter MCT1 distribution was unaffected by NMDA (Figures 
S1A-B). To confirm that NMDA promotes membrane insertion of GLUT1, we performed 
biotinylation assays with immunopanned oligodendrocytes (Figure 1B), revealing a two-fold 
GLUT1-increase at the cell surface following 30 min NMDA stimulation (Figure 1D), whereas 
the abundance of MCT1 was the same. To determine functional GLUT1 insertion, we expressed 
a glucose sensor (Takanaga et al., 2008) in transfected oligodendrocytes (Figure 1E). Activation 
of NMDA receptors caused a significantly increased FRET signal that was abolished by 7-CKA 
and D-AP5 which blocks both the glycinergic and glutamatergic NMDA receptor binding sites, 
respectively (Figure 1F). Calibration of the FRET sensor allowed to measure cytosolic glucose in 
oligodendrocytes, i.e. 0.560.04 mM at baseline and 1.850.24 mM following NMDA receptor 
stimulation (Figure 1G). Finally, we used immunopanned oligodendrocytes and quantified the 
uptake of 2-deoxyglucose (2DG) to confirm that NMDA elevates glucose import (Figure 1H). In 
these experiments, elevated glucose was not caused by inhibition of glycolysis, because the 
release of lactate was simultaneously enhanced. By NMR spectroscopy we calculated a 244% 
increase of U-13C-lactate release originating from U-13C6-labelled glucose (Figures 1I-K). As 
expected lactate release from cultured oligodendrocytes relies on glucose availability (Figure 
S1C-D). However, NMDA-stimulated lactate release was unexpected (Figures 1I-K and Figure 
S1E) because basic metabolic demands did not change and there were no signs of 
oligodendrocyte death (Figure S1F). Most likely, membrane repolarization (triggered by NMDA 
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receptor signalling and ion influx) consumes the additional ATP and leads to more glycolysis 
with lactate release.  
 
Myelination in vivo in the absence of oligodendroglial NMDA receptors 
Glucose is a major carbon source for lipid precursor metabolites, which are rate limiting for 
myelination (Rinholm et al., 2011). In vivo, reduced glutamate signalling might thus affect 
myelination during development. To study oligodendroglial NMDA receptor function, we 
crossed mice with a floxed NR1 allele (Tsien et al., 1996) to Cnp1Cre/+ mice (Lappe-Siefke et al., 
2003). NR1 (gene symbol Grin1) encodes the obligatory subunit of functional NMDA receptors 
(Tsien et al., 1996).  
In Grin1flox/flox*Cnp1Cre/+ mice (hereafter termed NR1 mutant or cKO, with Grin1flox/flox*Cnp1+/+ 
and Grin1flox/+*Cnp1Cre/+ being controls), NR1 was lost by immunostaining, as shown for optic 
nerve (Figures 2A, 2B and S2A), by qPCR of genomic DNA and by Western blot analysis 
(Figures 2C and 2D). Recombination analysis revealed that at P5, when the optic nerve is already 
populated with oligodendroglial precursor cells (OPCs), loss of the floxed allele was not yet 
significant. However, at P10, when many oligodendrocytes had matured and express Cnp1, 
about one third of the floxed alleles were excised, and recombination reached 62±8% at P96, 
when myelination is completed, matching the expected proportion of oligodendrocyte in adult 
optic nerves (Miller et al., 1985). Cre-mediated reporter expression in optic nerves demonstrated 
that virtually all recombined cells were of oligodendroglial origin (Figure S2B-C). The 
remaining 40 % NR1 signal from whole optic nerve immunostainings (Fig. 2B) or protein lysates 
(Fig. 2D) could be accounted for NR1 expression in astrocytes and OPCs.  
In purified myelin from mutant brains we found a strong reduction of GLUT1 (but not MCT1) 
compared to controls (Figures 2E, 2F, S1G-H) whereas total tissue GLUT1 was unchanged in 
NR1 mutants. By immunogold labelling of mature optic nerves, GLUT1 was localized in the 
myelin sheath, in the outer tongue, and the paranodal loops (Figure 2G), well positioned for 
functional glucose uptake into the system of myelinic channels. 
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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GLUT1 abundance in myelin sheaths of optic nerve axons was reduced by 80% in NR1 mutants 
compared to littermate controls (Figures 2H), in line with its NR1-dependent mobilization in 
cultured oligodendrocytes. 
GLUT1 mRNA is more abundant in mature oligodendrocytes than in precursor cells (Zhang et 
al., 2014). From CNS white matter samples, we amplified equal amounts of GLUT1 and MCT1 
cDNA when comparing mutants and controls, indicating that NMDA receptor signalling does 
not regulate GLUT1 at the level of gene expression (Figure S1I). Interestingly, we localized 
MCT1 by immuno-electron microscopy at both the outer and inner tongue of myelin (Figure 2I). 
Thus, lactate transporters are strategically positioned for taking up and supplying glycolysis 
products (Fünfschilling et al., 2012; Lee et al., 2012).  
Phenotypically, mutant mice were normally developed with functional white matter tracts, as 
shown for the optic nerve (Figures S3), and are long-lived. This suggests that NMDA receptors 
are not essential for myelination per se, in agreement with earlier reports (De Biase et al., 2011; 
Guo et al., 2012). However, the paucity of GLUT1 in myelin (Figures 2E, 2F and 2H) suggested 
reduced glucose import, which could affect the rate of myelin growth that is metabolically 
controlled (Rinholm et al., 2011). In the rodent optic nerve, the highest myelination rate occurs 
during the third postnatal week (Hildebrand and Waxman, 1984) and predicts the highest 
demands for glucose as a carbon sources for lipid synthesis at this time. Indeed, by EM we noted 
at ages P18-20 that myelin was thinner with fewer myelinated axons in the mutant optic nerves 
(Figures 3B, 3D-G). This difference was only transient as adult (P70) NR1 mutant optic nerves 
'catch up' and exhibit a normal myelin sheath thickness (Figures 3C, 3H-I).  
 
Functional analysis of myelinated axons 
To study function, we assessed optic nerve conduction at different stages of development by 
recording compound action potentials (CAPs) ex vivo, comparing NR1 mutant and controls 
(Figure S4). CAP profiles revealed a transiently reduced conduction velocity, again only at the 
peak of myelination (age P19-21) and mainly affecting small caliber axons (Figures S4D-F). 
These are best explained by the delay of CNS myelination (Figures 3D-I) as nerve calibre and 
axon numbers were normal (Figure S4J-K). The developmental delay of myelination in NR1 
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mutant optic nerves fits well the unexplained observation that demyelinating lesions repair less 
well when NMDA receptors are blocked (Li et al., 2013; Lundgaard et al., 2013).  
Next, we examined myelinated optic nerves under metabolic stress for their ability to recover 
from transient 'oxygen-glucose deprivation' (OGD), a well-established model of acute ischemia 
(Tekkok et al., 2007). Optic nerves were acutely isolated and CAPs were recorded ex vivo 
(Figures 4A, top). In these experiments, all optic nerves maintained conductivity (defined as 
'CAP area' of 1.0) and, within minutes after OGD onset, displayed block of nerve conduction, as 
illustrated by the rapid decline of CAP area (Figures 4A and 4B). When re-perfused 60 min later 
using oxygenated artificial cerebrospinal fluid (ACSF, 10 mM glucose), we determined some 
persistent loss of conduction in wild-type nerves, a Ca2+ dependent damage to axons (Tekkok et 
al., 2007). Surprisingly, in NR1 mutant nerves the recovery of axon function was further reduced 
by 50% (Figures 4C). NMDA-receptor mediated excitotoxicity in oligodendrocytes (Karadottir 
et al., 2005; Micu et al., 2006; Salter and Fern, 2005) may not be the main mechanism causing 
myelin damage (Hamilton et al., 2016). Indeed, ultrastructural damage following OGD alone, 
such as myelin delamination, was the same in NR1 mutants and controls (Figures S5A). Thus, 
further loss of axonal conductivity was not caused by more severe myelin injury, but rather by 
less efficient axonal recovery from the metabolic stress of OGD. Importantly, axonal recovery 
after OGD was normal prior to age P10 (Figures S6A), suggesting that axons require 
oligodendroglial support mostly after myelination, which limits rapid axonal access to 
extracellular metabolites (Nave, 2010).  
 
Causality of NMDA receptor signalling and glucose metabolism in axonal support 
To demonstrate causality between oligodendroglial glucose metabolism and axonal recovery, we 
asked whether lactate, permeating through MCT1 (Figures 2I), can replace glucose as an energy 
source and restore conduction independent of prior NMDA receptor signalling. As predicted, 
using lactate-containing ACSF for reperfusion, optic nerves from NR1 mutants recovered as well 
as control nerves and even better than in the presence of glucose (Figures 4D, E). This confirms 
that axons readily use lactate for ATP generation (Fünfschilling et al., 2012; Lee et al., 2012; 
Tekkok et al., 2005; Wyss et al., 2011). More importantly, it also proves that optic nerves in NR1 
mutants are not per se more susceptible to axonal injury. We confirmed this experimentally with 
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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MOG-induced experimental allergic encephalomyelitis (EAE), associated with secondary axonal 
dysfunction. Here, we found no difference in the onset of EAE symptoms or in clinical severity 
(Figures S5B-D), as indicated earlier (Guo et al., 2012; Matute, 2010).  
During OGD abnormal Ca2+-entry into the axonal compartment triggers axon loss probably 
resulting from excessive glutamate signalling caused by reversal of glutamate transporters 
(Stirling and Stys, 2010; Tekkok et al., 2007). Indeed, in the absence of free extracellular Ca2+ 
the axonal recovery was almost 100% in control nerves, yet remained significantly impaired in 
NR1 mutants (Figures S6E-F). Thus, glucose uptake by oligodendrocytes is critical to reenergize 
axons independent of Ca2+-mediated damage.  
We suggest that NMDA receptor signalling to oligodendrocytes enhances incorporation of 
GLUT1 into oligodendroglial and myelin membranes (providing 'hardware' of glycolytic 
support), specifically around axons of higher electrical activity. Interestingly, when optic nerves 
were acutely isolated from wildtype mice and tested an hour later, the prior application of D-
AP5, 7CKA or MK801 (30 min before the onset of OGD) did not visibly reduce axonal recovery 
from OGD (Figures S6F), in line with older reports (Tekkok et al., 2007). This is no 
contradiction to the mutant phenotype in vivo, however, because development and pharmacology 
operate at different time scales, and it could take hours or days to lose functionally exposed 
GLUT1 from the myelin compartment. Indeed, wildtype optic nerves maintained for an extended 
time ex vivo, and then tested for conductivity, revealed an intriguing effect of both NMDA and 
NMDA receptor blockers. In the presence of glucose and oxygen, their basic conduction 
properties appeared unchanged after 16 h (Figures S6G). We then studied axon function under 
metabolic challenge, but chose a more physiological and graded paradigm than OGD. Optic 
nerves were stimulated by short bursts with a gradual increase in frequency (between 1 and 
100Hz). As expected, the recorded CAPs declined as a function of increasing frequency (Figures 
4F). Interestingly, when nerves were pre-incubated for 16 h in the presence of 100 µM 
NMDA/Gly (mimicking glutamate release from spiking axons) high frequency conductivity was 
much better maintained (Figure 4F). For example, NMDA-stimulated nerves appeared well able 
to maintain axonal conduction at 25Hz, but without prior NMDA exposure axons stimulated at 
25Hz showed a functional decline of about 10% per min. Consistently, the decline of axonal 
conduction at increasing frequency of stimulation was even more aggravated when NMDA 
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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receptors had been blocked before by D-AP5 and 7CKA (Figure 4F). Taken together, these 
results strongly suggest that non-spiking axons lose oligodendroglial metabolic support over 
time.  
 
In vivo relevance of oligodendroglial NMDA receptor function  
To confirm our key finding also in vivo, we focussed on the spinal cord. Electrical stimulation of 
dorsal roots (L4) in anesthetized mice evoked stable CAPs that could be recorded from the dorsal 
columns (L1) (Figure 5A). We detected no overt differences between NR1 mutants and controls 
in spinal conduction properties or axon excitability (Figures 5B, C), confirming the overall 
integrity of myelinated tracts (Figures 5A, inset). Next, we monitored CAP (peak-to-peak) 
amplitudes following challenges at low (0.1Hz), medium (10Hz) and high frequency (100Hz). At 
low or medium frequency (for 10 min), we observed no difference between mutants and controls 
(Figures 5D). However, upon high frequency stimulation CAP amplitudes dropped significantly 
faster in mutant mice (Figures 5E, inset left). When allowed to recover at low frequency (0.1Hz), 
CAPs in mutant spinal cord recovered more slowly than in controls (Figures 5E, inset right).  
Myelinated axons vary in length, in diameter, and in firing frequencies, suggesting that their 
long-term energy demands differ greatly (Perge et al., 2012). We anticipated that NR1 mutant 
mice with a developmentally reduced presence of GLUT1 in myelin sheaths develop at least 
some signs of axonal pathology. We therefore examined white matter integrity in different CNS 
regions of adult NR1 mutants and controls, kept under normal cage conditions (10-12 months) 
and without specific challenges. While most white and grey matter regions in mutant mice, 
including optic nerves, appeared devoid of pathology within the first year (data not shown), such 
changes became detectable in white matter tracts of the medulla (Figures 6A and S7A). In 
longitudinal sections, we observed an increased abundance of reactive microglia and astrogliosis 
(Figures 6A-D). Also in spinal cord cross sections we occasionally noticed reactive microglia in 
white matter tracts of the dorsal and lateral columns (Figures S7B-C). By electron microscopy 
we observed myelin delamination and degenerating axons in cervical spinal cord sections 
(Figures 6E-F) that were not a feature of wildtype mice.  
The majority of myelinated axons in cortico-spinal tracts fire at a high frequency and comprise a 
high energy demanding white matter tract (Perge et al., 2012). We therefore performed a motor-
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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behavioural analysis to assess the function of spinal tracts in adult NR1 mutant mice. Indeed, 
even on a simple rotarod test 1 year old NR1 mutants revealed a significant deficit in 
performance when compared to age-matched controls (Figure 6G).  
At the age of 19 months NR1 mutants exhibited a severe neurological phenotype including hind 
limb clasping, hunchback and ataxia (Figure 6H) caused by ongoing neurodegeneration, which 
became visible already at 10 months. Signs of neuroinflammation and axonopathy were seen in 
all CNS white matter tracts (Figures 6I-L).  
 
Discussion 
Oligodendroglial metabolic support can explain why myelinated axons are vitally dependent on 
myelin integrity, independent of the myelin function in saltatory conduction (Griffiths et al., 
1998; Kassmann et al., 2007; Lappe-Siefke et al., 2003). However, the question arises how 
glycolysis in oligodendrocytes is matched to different axonal energy needs, and how excessive 
lactate production is avoided. Our study yields a novel working model, in which 
oligodendrocytes regulate glucose utilization by using NMDA receptor signals as a surrogate 
marker for axonal spiking activity (Figure 7). 
While NMDA receptors are widely studied in glutamatergic neurotransmission, the role of 
NMDA receptors in oligodendrocytes has remained enigmatic (De Biase et al., 2011; Guo et al., 
2012; Karadottir et al., 2005; Li et al., 2013; Lipton, 2006; Lundgaard et al., 2013; Micu et al., 
2006; Pina-Crespo et al., 2010; Salter and Fern, 2005; Yang et al., 2014). In myelin NR1 is 
associated with NR2C and NR3A subunits that provide a weak Mg2+ block (Burzomato et al., 
2010; Das et al., 1998), suggesting that calcium entry does not require prior membrane 
depolarization. In development, NMDA receptors are most abundant in oligodendrocyte 
precursors (De Biase et al., 2010; Zhang et al., 2014). Unfortunately, the early functions of 
glutamate signalling were not revealed by the deletion of NR1 in OPC (De Biase et al., 2011; 
Guo et al., 2012). It is possible that calcium permeable AMPA receptors compensate functions 
other than GLUT1 trafficking, which is specifically regulated by NMDA receptor signalling. 
This is reminiscent of hippocampal LTP, which also requires NMDA receptors and is not 
compensated by AMPA receptors alone (Tsien et al., 1996). 
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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Oligodendroglial NMDA receptors are localized in specialized microdomains of myelinating 
processes (Stirling and Stys, 2010; Stys, 2011) and also face the periaxonal space (Micu et al., 
2006). Is NMDA receptor-dependent regulation of GLUT1 in oligodendrocytes and the non-
compacted myelin compartment the same as GLUT4 regulation in other cell types (Bogan and 
Kandror, 2010)? In adipocytes, insulin-dependent GLUT4 trafficking requires calcium-
dependent myosin motors (Yip et al., 2008). We were unable to mobilize GLUT1 with insulin in 
oligodendrocytes, but when triggered with NMDA, trafficking was expectedly calcium 
dependent and required a stable microtubule network (data not shown).  
With the completion of developmental myelination, glycolysis products become gradually 
available to support the axonal energy metabolism, which is presumably more critical for fibers 
with high spiking activity. The ultrastructure of mature myelin is complex with narrow (non-
compacted) cytosolic compartments, in which glycolysis can take place. Once incorporated into 
these myelin membranes, glucose transporters are more likely to serve long-term functions than 
fast ('insulin-like') adaptations to changing energy needs. Indeed, our ex vivo experiment showed 
that it takes many hours for oligodendrocytes to metabolically respond to the loss of glutamate 
signalling. However, activity-dependent regulation of axonal energy metabolism may be 
clinically relevant, e.g. in the aging brain or in neurodegenerative diseases ("use it or lose it").  
It is therefore of interest that NR1 mutant mice, when kept in standard housing (i.e. without 
physical challenges), showed signs of neurodegeneration beginning in the medulla and spinal 
cord at 10 months of age and progressing later to all CNS white matter tracts. Here visible 
axonopathy and inflammation are most likely a "tip of the iceberg", reflecting reduced energy 
metabolism in (many more) myelinated axons in vivo. 
Finally, we note that also astrocytes can support axon function by releasing lactate in the white 
matter. They have direct access to the vasculature, store glycogen and rapidly respond to energy 
deprivation with glycogen breakdown (Brown and Ransom, 2007). Theoretically astrocytes may 
compensate some metabolic functions in oligodendroglial NMDA receptor mutants. The 
regulated metabolic interactions between axons, oligodendrocytes and astrocytes are increasingly 
recognized as key for normal white matter function and likely for axon survival in many 
neurodegenerative diseases.  
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
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Experimental Procedures 
Mouse strains 
Female Cnp1-Cre mice (RRID:MGI_3051754) (Lappe-Siefke et al., 2003) were crossbred to 
floxed NR1 (gene symbol Grin1) mice (RRID:MGI_2175051) (Tsien et al., 1996). Conditional 
knockout animals were Grin1flox/flox*Cnp1Cre/+ mice. As controls, we used Cnp1Cre/+, 
Grin1flox/flox*Cnp1+/+ or Grin1flox/+*Cnp1Cre/+ mice obtained as respective littermates. Some of 
the mice carried also the R26-stop-EYFP reporter gene for Cre activity 
(RRID:IMSR_JAX:006148) (Srinivas et al., 2001). Mice were maintained on the C57Bl6 
background. Experiments were carried out mainly on male mice. Animal experiments were 
performed according to German, Spanish and European guide lines for Animal Experimentation. 
Cell culture preparation 
Primary mouse or rat oligodendrocyte progenitor cells (OPCs) were isolated from cerebra 
cortices at P0-P2 as described previously (Barros et al., 2009; McCarthy and de, 1980). Cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM; Lonza) supplemented with 10% 
fetal calf serum, Glutamax (Invitrogen), Penicillin and Streptomycin (Invitrogen) at 37°C and 
5% CO2. Following OPC isolation cells were differentiated for 5 days in Sato’s medium. For all 
experiments, Glutamax was withdrawn from the growth medium in the last 12-16 h of 
differentiation. OPCs utilized for biotinylation assays, 2-deoxyglucose uptake or lactate release 
were further purified to 98.2±0.3% by negative selection immunopanning (Barres et al., 1992). 
Immunocytochemistry 
For GLUT1 and MCT1 immunocytochemistry, differentiated cells were treated for 30 min at 
37°C with 100 µM NMDA. Glycine as co-agonist for NMDA receptors was already present in 
the medium. NMDA receptor blockers D-AP5 and/ or 7CKA (100 µM) were applied 30 min 
prior to NMDA stimulation. Plasma membranes of mature oligodendrocytes were labelled with 
anti-galactocerebroside (GalC) antibody (Millipore Cat# MAB342 RRID:AB_94857) for 15 min 
at 37°C prior to fixation with 4% paraformaldehyde for 10 min at RT. Cells were permeabilized 
with ice-cold methanol for 5 min, washed with PBS, and incubated with anti-GLUT1 antibody 
(Abcam Cat# ab32551 RRID:AB_732605) or with anti-MCT1 (Millipore Cat# AB1286 
RRID:AB_90565) overnight at 4°C. Analysis was carried out on confocal stacks of individual 
cells using ImageJ (http://rsb.info.nih.gov/ij/). Data are presented as the ratio of GLUT1 or 
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MCT1 signal area to GalC area. 3 individual experiments with 14-24 cells per condition were 
analyzed. Data grouped per experiment and normalized to control condition. 
Cell surface biotinylation 
Immunopanned oligodendrocytes were treated with NMDA receptor agonists or antagonists as 
described above. Cell surface-associated proteins were labelled by incubation with 0.5 mg/ml 
membrane impermeable EZ-link Sulfo-NHS-Biotin (Thermo Scientific) at 4°C for 30 min. After 
removing unbound biotin, cells were lysed for 15 min on ice with 1% Triton X-100, 0.2% SDS 
in PBS (pH 7.4) containing protease/phosphatase inhibitors. To isolate biotinylated proteins, 
350-450 µg of lysate was incubated overnight at 4°C with 150 µl of 50% Pierce Streptavidin 
Agarose Resin in PBS (pH 7.2). After elution of biotinylated material, proteins were resolved by 
SDS-PAGE and immunoblotted with anti-GLUT1 or anti-MCT1 antibodies as described below. 
Glucose sensor imaging 
Rat mixed glial cells (after 8-12 days in culture) were transfected (using Fugene HD, Roche) 
with glucose sensor FLII12Pglu-700µΔ6 [(Takanaga et al., 2008); Addgene plasmid 17866]. 
One day after transfection OPCs were isolated and further cultivated for 5 days. For details on 
FRET imaging see Supplemental Information. NMDA receptors agonists and antagonists (each 
100 µM) were applied and FRET changes were analyzed. For control experiments and sensor 
calibration (Bittner et al., 2010) cells were incubated without glucose or adding either 
iodoacetate (glycolysis inhibitor, 1 mM) or cytochalasin B (glucose transporter blocker, 40 µM).  
2-deoxyglucose uptake measurements 
Immunopanned oligodendrocytes differentiated for 5 days were incubated for 25 min in the 
presence or absence of NMDA/ Gly (100 µM) in a modified medium (in mM: NaCl 91.17; KCl 
5.37; NaH2PO4 0.91; Na2HPO4 0.23; NaHCO3 17.86; MgSO4 0.81; CaCl2 1.8; NaOH 16.7; 
HEPES 20; glucose 10; adjusted to pH 7.4 with HCl after equilibration with 5% CO2). Then 
glucose was replaced by 10 mM 2-deoxyglucose (2DG) for 5 min. 2-deoxyglucose-6-phosphate 
present within the cells was quantified using a commercial kit according to the instructions of the 
manufacturer (Cosmobio).  
Measurements of lactate release by NMR 
Immunopanned oligodendrocytes were differentiated for 4 days in Sato’s medium containing 25 
mM unlabelled glucose, and for an additional day in Sato’s medium containing 25 mM U-13C6-
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glucose. 100 µM NMDA/ Gly was added for 30 min at 37°C in modified medium (see above) 
containing U-13C6-glucose. Conditioned media was immediately collected and snap frozen until 
NMR analysis. For details on NMR analysis see Supplemental Information. 
Immunohistochemistry 
For NR1 labeling mice were perfused with ice cold artificial cerebrospinal fluid (ACSF). Optic 
nerves were isolated and immersion fixed with 4% PFA for 2 h at RT and prepared for later 
cryo-sectioning. Slide-mounted sections (12 µm) were air dried at RT and then treated with 0.3% 
Triton X-100 and 5% horse serum for 1 h. Primary antibodies for NR1 (1:250, Millipore Cat# 
MAB363, RRID:AB_94946) and MBP (1:300, rabbit, Dako) were incubated overnight at 4°C in 
same solution. Secondary antibodies were incubated in 2% horse serum for 2 h at RT.  
For analysis of local inflammation and pathology paraffin sections of perfusion fixed tissues 
were used. Sections were treated with primary antibodies diluted in PBS/BSA (1% w/v BSA) 
overnight at 4°C. Dilutions were as follow: for GFAP (1:200, mouse, Novocastra), Mac3 (1:400, 
rat, BD Pharmingen) and APP (1:1000, Millipore Cat# MAB348 RRID:AB_94882). 
Biotinylated secondary antibodies were then incubated for 30 min at RT and chromogenic 
staining was completed using HRP-DAB detection. 
Protein analysis 
Protein lysates of optic nerves from individual mice were prepared using the Precellys Ceramic 
Kit 1.4 mm and the Precellys 24 homogenizer (Peqlab). Nerves were homogenized in 150 µl 
sucrose buffer (in mM: 320 sucrose, 10 Tris (pH 7.4), 1 NaHCO3 and 1 MgCl2) and protease 
inhibitors (Complete tablets, Roche). For Western blotting 30 µg protein lysate was size-
separated on 12% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes 
following instructions from BioRad. Primary antibodies to NR1 (1:500, Millipore Cat# 
MAB363, RRID:AB_94946) and GAPDH (1:2000, Enzo Life Sciences Cat# ADI-CSA-335-E, 
RRID:AB_2039148) were diluted in blocking buffer (5% milk) and incubated overnight at 4°C. 
Membranes were washed in 0.05% Tween prepared in phosphate buffer (PBS-T) followed by 
incubation with a horseradish peroxidase-conjugated secondary antibody. Proteins were detected 
with an enhanced chemiluminescence kit (Western Lightning™, Perkin Elmer) according to the 
manufacturer’s instructions. Exposed ECL films (Amersham Biosciences) were scanned at 
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greyscale (300 dpi resolution) using a regular image scanner, followed by densitometric analysis 
with ImageJ. The peak intensity for NR1 was normalized to the peak intensity of GAPDH.  
Immunoelectron microscopy 
Freshly dissected optic nerves were immersion fixed with 4% formaldehyde and 0.2% 
glutaraldehyde in 0.1 M phosphate buffer containing 0.5% NaCl. After embedding in 10% 
gelatine and subsequent infiltration with 2.3 M sucrose in 0.1 M PB overnight, small blocks of 
gelatine containing optic nerve pieces were mounted onto aluminum pins for ultramicrotomy and 
frozen in liquid nitrogen. Ultrathin cryosections were picked up with a 1:1 mixture of 2 % 
methylcellulose and 2.3 M sucrose. Sections were incubated with antibodies against GLUT1 
(1:100, Abcam Cat# ab32551 RRID:AB_732605) and MCT1 (1:1000, Millipore Cat# AB1286 
RRID:AB_90565) and detected with protein A-gold (10 nm, obtained from the Cell Microscopy 
Center, Department of Cell Biology, University Medical Center Utrecht, NL), and by anti-
chicken immunogold (10 nm, Aurion), respectively. Sections were analysed with a LEO 
EM912AB (Zeiss) and digital micrographs were obtained with an on-axis 2048x2048-CCD 
camera (TRS, Moorenweis). For quantification 10-12 randomly taken images from 3 controls 
and 3 NR1 mutants were assessed. Per image all myelinated axons and immunogold particles 
associated with myelinated axons were counted, and a ratio of immunogold particles to the 
number of myelinated axons was calculated. The mean ratio per animal was then normalized to 
controls.  
Myelin preparation and immunoblotting 
Myelin was purified as described before (Norton and Poduslo, 1973) from mouse brain 
homogenate in 0.32 M sucrose. Immunoblotting was performed as described before (Werner et 
al., 2007). Briefly, 30 µg protein were separated on 10% polyacrylamide-SDS-gels, blotted onto 
polyvinylidene difluoride membranes (Roche), and incubated with primary antibodies for 
GLUT1 (1:500, Abcam Cat# ab32551 RRID:AB_732605), MCT1 (1:1,000, Millipore Cat# 
AB1286 RRID:AB_90565) and SIRT2 (1:2,000) (Dryden et al., 2003). Blots were incubated 
with horse radish peroxidase-coupled secondary antibodies (Dianova) and developed by 
enhanced chemiluminescence (Western Lightning ECL, Perkin Elmer) using a luminescence 
imager (Intas).  
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Electron microscopy and morphometry 
Optic nerves were acutely removed and either immersion-fixed for conventional sample 
preparation or cryofixed by high-pressure freezing (HPF) and freeze substituted as described in 
detail (Möbius et al., 2010). For analysis of axonal pathology animals were perfusion-fixed (4% 
formaldehyde, 2.5% glutaraldehyde). For structural analysis of optic nerves that were subjected 
to OGD, nerves were directly immersion-fixed (4% formaldehyde, 2.5% glutaraldehyde). For 
analysis of unmyelinated, myelinated and ensheathed axons (defined as 1 – 3 uncompacted 
layers) 4-6 EM images with 12,000x magnification 400-700 axons were counted for each nerve. 
Data were grouped per animal. For g-ratio analysis 4-5 random overview pictures were taken at 
8,000x magnification, 200 axons analyzed using ImageJ (images were blinded for experimenter). 
G-ratios (axonal diameter divided by the fiber diameter including the myelin sheath) were 
calculated from circular areas equivalent to the measured areas of axons and myelin sheath 
including the axon. 
 
Optic nerve recordings 
Following anaesthesia and decapitation, nerves were gently removed, placed into an interface 
perfusion chamber (Haas Top, Harvard Apparatus) and superfused with ACSF containing the 
following (in mM): 124 NaCl, 3.0 KCl, 2.0 CaCl2, 2.0 MgSO4, 1.25 NaH2PO4, 23 NaHCO3, and 
10 glucose. Perfusion chamber was continuously aerated by a humidified gas mixture of 95% 
O2/5% CO2 and experiments were performed at 37°C.  
For oxygen-glucose deprivation (OGD) the protocol was performed as described previously 
(Baltan et al., 2008). CAPs were elicited every 30 s and OGD (applied for 60 min) was induced 
by switching to glucose-free ACSF and a gas mixture containing 95% N2/5% CO2. After OGD 
control ACSF and O2 were restored and CAPs were recorded for up to 2-3 h; responses 
stabilized within 20-30 min. When L-Lactate (20 mM, Sigma) was used during recovery it was 
substituted for 20 mM NaCl.  
CAP area is proportional to the total number of excited axons (Stys et al., 1991). Irreversible 
injury was measured by determining residual CAP area 1.5-2 h after conclusion of OGD, 
normalized to baseline CAP area.  
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For the long-term ex vivo analysis, wildtype nerves were continuously superfused with ACSF 
containing either NMDA and glycine (NMDA/ Gly 100 µM), NMDA/ Gly plus 7CKA and D-
AP5 (7CKA/ D-AP5 100 µM) or DMSO only (DMSO Control). After 16 h of treatment CAPs 
were recorded at 0.2Hz to obtain baseline and then nerves were challenged with a gradual 
increase in stimulation frequency (from 1 to 100Hz) with each stimulus train lasting 30 s. For 1 
and 5Hz stimulations CAPs were continuously recorded. For 10, 25, 50 and 100Hz stimulations 
CAPs were sampled after a burst of each 100 stimuli with an inter-burst interval of 300 ms. CAP 
area of the graded responses were analysed for each treatment group (2.1 ms after stimulus 
onset) and normalised to baseline.  
 
In vivo spinal cord CAP recordings 
For details see Supplemental Information. Stimulation and recording from spinal cord axons in 
vivo were performed with bipolar platinum electrodes. Square-wave constant voltage pulses (100 
µs) were used to stimulate the dorsal root L4 and CAPs were recorded from the ipsilateral 
fasciculus gracilis at spinal cord level L1. Dorsal roots were stimulated at different frequencies 
(0.1, 10 and 100Hz) and CAP recordings sampled at 50kHz. Distance between the electrodes 
was measured using a thin cotton thread to evaluate conduction velocities. For analysis of axonal 
firing strength, the peak-to-peak amplitude (of the first and most robust peak of the CAP 
recording) was monitored over time and normalized to baseline (0.1Hz).  
 
Rotarod and clinical score 
Mice (10-12 months) were placed on a horizontal rod at 1 rpm and accelerated with 1 rpm every 
10 s (3 tests per trial). The clinical scores at age 19 months were: 0: asymptomatic, 1: hind limb 
clasping, 2: additionally hunchback visible, 3: additionally slipping during walking on a grid, 
3.5: additionally not able to hold on an inverted grid 4: additionally hind limb ataxia, not able to 
hold on an upright grid and reduced righting reflex, 4.5: spastic hind limbs. 
 
Statistical analysis 
Inter-group comparisons were done by Mann Whitney t test or two-tailed Student t test. For 
multiple comparisons data was analysed with one-way or two-way ANOVA with Bonferroni’s 
DOI: http://dx.doi.org/10.1016/j.neuron.2016.05.016 
 
Page 18 of 28 
post-test or using linear mixed effects models (lme4 package version 1.1.9; https://CRAN.R-
project.org/package=lme4). All analyses were conducted through GraphPad Prism 4 or R 
(version 3.2.2, R Core Team, 2015). The levels of significance were set as * P < 0.05; ** 
P < 0.01; *** P < 0.001. Data are represented as means ± SEM. 
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Figure legends 
Figure 1 
NMDA stimulates GLUT1 surface expression and glucose uptake by cultured 
oligodendrocytes. 
A, Oligodendrocyte immunostained for GLUT1 and GalC. NMDA receptor stimulation 
mobilizes GLUT1 and increases its cell surface expression, which is blocked by D-AP5. Scale 
bar, 20 µm. 
B, GLUT1 and MCT1 immunoblots following cell surface biotinylation of immunopanned 
NMDA-treated oligodendrocytes and controls. 
C, Quantification of the experiments in a giving the ratio of GLUT1:GalC stained area in n=3 
experiments and 20-24 cells per condition (*P<0.05, **P<0.01 one-way Anova with 
Bonferroni’s multiple comparisons test). 
D, Quantification of the experiments in b, normalising biotinylated to total protein (P=0.03, n=3; 
paired t test). MCT1 surface expression is unchanged.  
E, FRET imaging of oligodendrocytes expressing a glucose sensor (Takanaga et al., 2008) 
(FLII12Pglu-700µΔ6). Intracellular glucose levels (normalized to baseline FRET signals, n = 4) 
drop with addition of cytochalasin B (CytB, glucose transporter blocker) or increase with 
iodoacetate (IA, glycolysis inhibitor). Note that intracellular glucose is rapidly phosphorylated 
and undetectable. 
Inset: oligodendrocyte transfected with the glucose sensor and counterstained for MBP. Note that 
the sensor is mainly located in the soma and main processes. Scale bar 20 µm. 
F, NMDA receptor stimulation (by applying 100µM NMDA and glycine) increases FRET 
signals that can be blocked by the addition of 7CKA and D-AP5 (FInteraction(251,7109)=1.96, 
P<0.0001, two-way Anova).  
G, Quantification of calibrated FRET signals of NMDA-stimulated oligodendrocytes (26-28 
min), compared to baseline and cells receiving also 7CKA and D-AP5 (***P<0.001, one way 
Anova with Bonferroni’s multiple comparisons test). 
H, Immunopanned oligodendrocytes stimulated with NMDA/Gly (25min) before switching to 2-
deoxyglucose (2DG, 10 mM, 5 min). Increased 2DG uptake was blocked by 7CKA and D-AP5 
(n=5 experiments, *P<0.05, **P<0.01; paired t test).  
I, 13C, 1H-HSQC Spectra at 700MHz corresponding to proton resonance from the culture 
medium of immunopanned oligodendrocytes 30 min after exposure to NMDA/Gly (top) and 
controls (bottom). Boxed: lactate signals. Quantification by comparison of the peak volume of 
lactate methyl group to the internal standard DSS.  
J, Increase lactate following NMDA/Gly treatment, depicted by overlaying the 1D-1H slices of 
spectra in the lactate methyl signal range. 
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K, Lactate release after NMDA receptor stimulation increased to 1244% (n=4 paired NMR 
experiments, P=0.023 paired t test).  
 
Figure 2 
Oligodendroglial NMDA receptor mutants with reduced GLUT1 incorporation into myelin  
A, Immunostaining of NR1 in optic nerve cross sections at age P80 from control and NR1 cKO 
mice (left panel). Higher magnifications (middle and right panel) reveals NR1 (green) is absent 
from mutants and overlaps with MBP (red) in control mice. Scale bars, 20 µm (left) and 1 µm. 
See also Figure S2A. 
B, Quantitation of NR1 staining intensity from whole optic nerve sections (n=3; P=0.019, 
Student t test).  
C, Cre-mediated recombination of genomic DNA in individual optic nerves of each genotype as 
quantified by qPCR. Depicted is the relative abundance of the floxed NR1 allele after 
recombination (normalized to the abundance in NR1fl/fl littermate controls, defined as 100 % at 
different ages). In NR1 mutant nerves the abundance of NR1 flox copies was determined at ages 
P5 (9822 % flox copies remaining; n = 5 vs 4, P = 0.939), age P10 (697%; n=4, P=0.0119), 
age P16 (604%; n=4 vs 3, P=0.0024) and P96 (382%; n=4 vs 9, P<0.0001).  
D, Western blot analysis of NR1 expression in individual nerves from mutant and control mice at 
age P75. Quantification revealed a reduction by 6112% in NR1 cKO nerves (n=3, P=0.0079). 
GAPDH, loading control. 
E, By Western blotting, GLUT1 is reduced in purified myelin of NR1 mutants (Sirt2, loading 
control). 
F, Quantification of E (n=3; P=0.008, Student t test) 
G, Localization of GLUT1 by immunoglod labelling. In optic nerve cross sections GLUT1 was 
detected in myelin sheaths, the outer tongue and paranodal loops. Scale bar 200 nm. Gold 
particles, red arrows 
H, Reduced abundance of immunogold labelled GLUT1 in myelin of NR1 mutant optic nerves 
when compared to littermate controls (10-12 randomly taken images per animal, n=3; P=0.0025, 
Student t test).  
I, By immunogold labelling MCT1 is associated with adaxonal (outer tongue) and abaxonal 
(inner tongue) myelinic channels, without difference between mutants and controls. Scale bar, 
100 nm. 
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Figure 3 
Myelination in the absence of oligodendroglial NMDA receptors in vivo 
A-C High-pressure-freezing (HPF) electron microscopy of the developing optic nerve. 
Overview of optic nerve cross sections from control and NR1 mutant mice at P10 (A), P20 (B) 
and P70 (C). At early and late stages NR1 mutant nerves are indistinguishable from controls. A 
minor hypomyelination is apparent at P20. Scale bars 0.5 µm (A, B) and 0.2 µm (C). 
D, Electron microscopy of conventionally fixed optic nerves from mutant and controls, with 
unmyelinated (U), ensheathed (E) and myelinated (M) axons. Scale bar, 1µm.  
E-I, Axon size distribution and myelin sheath thickness (g-ratio) at P18 and P70.  
E, Diameter spectrum of myelinated axons with relatively more myelinated small caliber axons 
in control nerves than in NR1 cKO at P18 (***P<0.001, two-way Anova, Bonferroni’s post-
test).  
F, Cumulative frequency of g-ratios (low to high) measured for individual optic nerves of each 
genotype. Note the significant shift to higher g-ratios in P18 NR1 mutants (inset: means±s.e.m. 
of all g-ratios for two axon size groups).  
G, At P18, myelinated (M) axons are transiently reduced in mutant optic nerves, unlike the 
number of unmyelinated (U) and merely ensheathed (E) axons (400-700 axons counted per 
nerve; n = 3, P = 0.048). 
H,I At P70, axon size distribution and optic nerve g-ratios are similar in mutants and controls. 
 
Figure 4 
Axonal energy metabolism regulated by NMDA receptor and GLUT1-dependent lactate 
export from myelinating oligodendrocytes  
A, top: Scheme of recording compound action potentials (CAP) from acutely isolated optic 
nerves. After 1h, nerves were subjected to 60min oxygen glucose deprivation (OGD) followed 
by reperfusion with ACSF containing 10mM glucose. 
bottom: Optic nerve 'CAP areas' (i.e. area underneath CAPs as shown in C) normalized to 
baseline. Note the rapid decline of nerve conduction and the incomplete recovery after 
reperfusion, which is more pronounced in NR1 mutants (red) compared to controls (black).  
B, Averaged optic nerve CAPs during baseline, OGD and recovery phase in control (top) and 
NR1 cKO (bottom).  
C, Quantification of data in (A) with reduced functional recovery after OGD in mutants (n=12) 
versus controls (n=11, P=0.0046, Student t test). 
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D, With 20 mM lactate, the functional recovery after OGD was the same in NR1 mutants (n=6) 
and controls (n=8). 
E, Axonal recovery at higher temporal resolution, comparing 10mM glucose (glc) and 20mM 
lactate (lac). Depicted are fitting curves (lines, Boltzmann fit) for the average CAP area over 
time (P<0.0001, two-way Anova comparing glucose and lactate in NR1 mutants). 
F, Wildtype optic nerves, maintained functional ex vivo for 16 hours in the presence of NMDA/ 
Gly (100µM), or NMDA/Gly plus 7CKA/ D-AP5 (100µM) or only DMSO (control), were 
subsequently challenged with increasing stimulation frequencies. Note that nerves treated with 
NMDA/Gly show less decline of CAP area at higher frequency (P<0.0001 two-way Anova with 
Dunnett’s multiple comparisons test, n=6 nerves for each treatment group).  
 
Figure 5 
Requirement of oligodendroglial NMDA receptors for high frequency conduction 
A, Scheme of stimulating DRG axons of lumbar segment L4 and recording from fasciculus 
gracilis at L1 (inset: intact myelination of spinal cord in mutants and controls, Gallya's stain).  
B, Representative CAPs (averaged) in control (top) and mutants at age 4-6 months. Dotted line: 
peak-to-peak amplitude used to analyse firing strength of fastest axon groups. Conduction delays 
were unchanged.  
C, Normal axonal excitability in mutants measured at increasing stimulus intensities with peak-
to-peak amplitude normalized to maximal readings.  
D, After 10 min at 0.1Hz, stimulation frequency increased to 10Hz (medium frequency 
stimulation, MFS), showing no difference between mutants (n=6) and controls (n=3).  
E, 100Hz (high frequency stimulation, HFS) caused a decrease of firing strength (within 
seconds) that was significantly faster and stronger in NR1 mutants (n=7) than controls (n=5). 
Left inset: higher temporal resolution for indicated region, Finteraction (119,1190) = 3.07, 
P < 0.0001, two-way Anova). Right inset: slower recovery of CAPs at the end of HFS, 
monitored at 0.1Hz (τ calculated from normalized exponential fits, P=0.0084, Students t test). 
 
Figure 6 
Late onset neuroinflammation and axonopathy in NR1 cKO mice 
A, Indirect signs of neurodegeneration in white matter tracts at 1 year of age and overview (left) 
of sagittal cerebellum-spinal cord section from NR1 cKO mice. Signs of local inflammation 
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(Mac3 immunostaining) were more obvious in the ventral white matter (vWM) compared to 
spinal cord grey matter (GM). Higher magnification (region marked by a red rectangle) reveals 
activated microglia (Mac3). Scale bar 20 µm. See also Figure S9. 
B, Neuroinflammation in the ventral white matter of NR1 cKO mice confirmed by increased 
density of cell nuclei (P = 0.029, n = 4, Student t test ). In adjacent GM nuclear densities are 
unaltered.  
C, Quantification of the Mac3+ immunostained area (microgliosis) in vWM of NR1mutant mice 
(P = 0.0004, n = 4, Student t test) 
D, Quantification of the GFAP+ area (astrogliosis) in vWM of NR1 mutant mice (P = 0.013, 
Student t test).  
E, F, By electron microscopy of ventral cervical spinal cord cross sections, ultrastructural 
features of axonal pathology and degeneration were more frequent in NR1 mutant mice 
compared to controls (n =4-5 mice with 12-14 randomly taken images, covering 530 µm2 each, 
P = 0.0014, Student t test). Scale bar 2 µm. In E, A = Axonal degeneration; B = Blebbing 
membranes; D = Delamination; N = Normal myelin.  
G, Motor deficits of NR1 cKO mutants at 10 -11 months of age, demonstrated by Rotarod 
testing on three consecutive days (repeated the following month). The latency to fall is decreased 
in NR1 mutant mice (red line) compared to littermate controls (FGenotype (1,17) = 4.95, P = 0.040, 
n = 9-10, two-way Anova).  
H, At age 19 months, NR1 cKO mice (n = 11) display significant neurological deficits (n = 8, P 
< 0.001 Student t test). Clinical scores are 0: asymptomatic, 1: hind limb clasping, 2: additional 
hunchback visible, 3: additionally frequent slipping while walking on grid; 3.5: additionally 
failure to hold on inverted grid; 4: additionally hind limb ataxia and unable to hold on upright 
grid; 4.5: spastic hind limbs. 
I, Brain sections of 19 months old NR1 cKO mice immunostained for Mac3+ show widespread 
signs of neuroinflammation in white matter tracts; corpus callosum and fimbria are magnified 
(right panel) 
J, Quantification of Mac3+ immunostained area in NR1 mutants compared to littermate controls 
and age matched Cnp1Cre/+ mice (n = 4-6 mice, P < 0.001, linear mixed effects analysis with 
post-hoc Tukey correction for multiple comparisons). 
K, Axonopathy in white matter tracts revealed by APP immunolabelling (arrow heads) in brain 
sections of 19 months old NR1 cKO mice; corpus callosum, fimbria and subventricular white 
matter are shown. 
L, Quantification of APP spheroids in NR1 mutants in comparison to littermate controls and age 
matched Cnp1Cre/+ mice (n = 4-6 mice, Control vs. NR1 cKO P < 0.001 and Cnp1Cre/+ vs NR1 
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cKO P = 0.03, linear mixed effects analysis with post-hoc Tukey correction for multiple 
comparisons) 
 
Figure 7 
Schematic depiction of oligodendroglial NMDA receptor signalling  
Working model in which axonal electrical activity in developing white matter tracts constitutes a 
glutamatergic signal for the surrounding OPC/oligodendrocytes/myelin compartments (1). After 
myelination NMDA receptors associated with the internodal/paranodal membrane respond to 
axonal glutamate release as a surrogate marker for increased axonal electrical activity and energy 
needs, causing (2) the incorporation of additional glucose transporters into oligodendrocytes and 
myelin and the adaptation of glucose uptake (feed-forward regulation). Glycolysis products (3) 
are initially used for ATP and lipid synthesis (4). Later, mature oligodendrocytes release lactate 
(or pyruvate) to fuel the axonal compartment (5) for mitochondrial ATP production (6). 
Regulation of oligodendroglial glucose uptake by axonal energy needs could help prevent 
abnormal accumulation of lactate. The possible effect of glutamate on glucose transporters on 
astrocytes is not shown. 
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 Figure S1 (Related to Figure 1 and 2). Oligodendroglial MCT1 expression is not altered by NMDA receptor stimulation in 
culture, lactate release from primary oligodendrocytes, and MCT1 abundance in myelin is unchanged in NR1 mutant mice.  
A, B Immunolabelling of MCT1 in primary oligodendrocytes revealed readily detectable signals at the cell surface. NMDA 
receptor stimulation for 30 min did not cause any overt MCT1 redistribution, when quantified and normalized to GalC surface 
staining. Scale bar 10 µm. 
C, Lactate release by cultured oligodendrocytes depends on glucose levels in the medium (note Km for Glut1 is ~ 3 mM).  
D, Dose-dependent inhibition by cytochalasin B (CytB), a glucose transporter blocker, reduces lactate release into the medium 
(containing 10 mM glucose) of oligodendrocytes. 
E, Activation of NMDA receptors increases lactate release by 18 % ± 6 % compared to untreated conditions and is specifically 
blocked by 7CKA or D-AP5 (** P < 0.01, n = 5-6; Mann Whitney t test). 7CKA and D-AP5 were used to block the glycinerig 
and glutamatergic binding site of NMDA receptors, respectively.  
F, Measurement of lactate dehydrogenase (LDH), 60 min after the addition of 100 µM NMDA/Gly to the culture medium, 
yields no evidence for oligodendrocyte death by excitotoxicity. 
G, H, Western blot analysis of MCT1 in myelin and in total brain lysates from NR1 mutant and control brains. When 
quantified, MCT1 protein abundance in myelin is not different between NR1 mutants and controls. SIRT2 was used as a 
loading control 
I, mRNA expression of GLUT1 and MCT1 was not significantly altered when comparing samples from enriched white matter 
of NR1 mutants and littermate controls.  
 
B, Cnp1-Cre*ROSA26-floxed-STOP-EYFP mice reveal reporter gene expression in recombined cells of the optic nerve at 
P15. Confocal sections were immunostained for EYFP (with anti-GFP antibody to enhance reporter signal) and CC1 (mature 
oligodendrocytes), for EYFP and NG2 (OPCs), and for EYFP, GFAP (astrocytes) and IBA1 (microglia). Arrows indicate 
mature oligodendrocytes positive for EYFP and CC1. Arrowheads indicate OPC (immunostained for NG2, middle) or 
astrocytes (immunostained for GFAP, bottom) that are EYFP negative. Asterisks indicate microglia (immunostained for IBA1 
but not EYFP). Scale bars 10 µm.  
C, Reporter analysis at P80. Epifluorescent overview of longitudinal optic nerve section stained for EYFP and CNP (mature 
oligodendrocytes). DAPI staining labels nuclei. At higher magnification (bottom) there is a virtually complete overlap of 
EYFP reporter and CNP expression. Scale bars 20 µm (top), 10 µm (bottom). 
  
Figure S2 (Related to Figure 2). Targeting NR1 gene 
expression in oligodendrocytes and cre-mediated 
reporter gene expression in the optic nerve. 
A, Immunostaining of the NR1 subunit in longitudinal 
nerve sections (scale bars 50 and 10 µm) at age P80. 
Higher magnifications exhibit a co-localization of NR1 
(green) and MBP (red) on oligodendrocyte processes in 
control nerves, and a strong reduction of the NR1 signal 
in mutant nerves. Note the NR1(green)-positive 
processes of MBP (red)-negative cells (bottom-left), 
presumably OPC. NR1(green)-positive processes are 
absent from the NR cKO nerves (bottom-right). 
 
 
Figure S3 (Related to Figure 3). Behavioural assessment of visual acuity and contrast sensitivity.  
A, Visual acuity and contrast sensitivity were measured with a virtual-reality optomotor system. Scheme modified from 
(Prusky et al., 2004) with permission.  
B, Visual acuity was measured with moving gratings of increasing spatial frequency (in cycles per degree = cyc/deg), until the 
mice stopped tracking. NR1 mutant and littermate controls were examined at 2-3 months and at 12-13 months of age but 
revealed no difference of performance between genotypes.  
C, D, Assessment of contrast sensitivity was with stimuli of distinct spatial frequencies that were presented at different contrast 
levels (1 corresponds to 100 % and 20 to ~ 5 % contrast, see icons (left)). No overt differences were observed between 
genotypes. 
  
 
 
Figure S4 (Related to Figure 3). Optic nerve conduction during postnatal development. 
A, D and G, Representative traces of compound action potentials (CAPs) recorded from acutely isolated optic nerves at three 
different ages (P9-10, P19-21, and P50-70). Nerves were stimulated with 0.8 mA every 30 s for 15 min. Traces represent CAP 
averages. B, E and H, Axon excitability of optic nerves measured at different stimulus intensities (0 – 1 mA) in 0.1 mA steps. 
The CAP area of each stimulus step is normalized to that of maximal stimulation (1 mA).  
C, F and I, Peak latencies of averaged CAPs, recorded at the corresponding ages.   E, At ages P19-P20, when all optic nerve 
axons are myelinated, mutant optic nerves displayed a reduction in axon excitability: Finteraction (10, 209) = 1.97, P = 0.039, 
Fgenotype (1, 209) = 11.71, P = 0.0007, two-way Anova. At stimulus intensities up to 0.3 mA, nerves from controls responded 
with 58 ± 7 % and nerves from NR1 cKO with 39 ± 5 % of maximal response at 1 mA, ** P < 0.01, two-way Anova, 
Bonferroni post-test.  
F, The conduction delay of peak 3 from NR1 mutants was significantly increased at P19-20  (1.85 ± 0.05 ms vs. 2.04 ± 0.06 
ms in control and NR1 cKO, respectively, P < 0.01, two-way Anova, Bonferroni posttest). In contrast, in unmyelinated (a – c, 
P9-10) and in adult, fully myelinated optic nerves (g – i, P50-70) the conduction properties were equal between controls and 
NR1 mutants. 
J, Semi-thin cross sections from epoxy-embedded optic nerves at P18 from control (left) and NR1 cKO (right) mice. No overt 
difference was observed in nerve cross section area (3 nerves per genotype analysed). Scale bar 100 µm.  
K, Total axon number was not altered in NR1 cKO optic nerves (80520 ± 1875) compared to littermate controls (77680 ± 
1650, n =3, P = 0.32 Student t test). For each optic nerve 400-760 axons from 5-8 randomly taken EM images were counted. 
Average axon density of each nerve was multiplied with the average total cross section area subtracted from the fraction of 
non-axonic (glial cell bodies and processes) area. 
 
  
 
 
Figure S5 (Related to Figure 4). NR1 mutant white matter tracts are not more vulnerable to injury. 
A, Electron microscopic inspection of optic nerves that were subjected to 1 h baseline (upper panel) and 1 h oxygen glucose 
deprivation (OGD) (middle and lower panel). Ultrastructural damage such as occasional loosening of the myelin sheath (red 
arrowheads) was identical in both controls and NR1 mutants. In both genotypes there were no morphological signs of 
oligodendrocyte (OL) death (lower panel). Scale bar 1 µm. 
B, Time course of EAE-associated neurological symptoms. Control mice (n=19) and NR1 cKO mice (n=18) were immunized 
with MOG35-55 peptide and exhibited similar EAE scores, with no difference in the onset of symptoms or severity (see 
Methods for score). 
C, The axon conduction latency in the corticospinal tract of mice with chronic EAE (measured at the end of the EAE 
experiment) was similar in both groups of animals (control 5.15 ± 0.17 ms (n = 11) vs NR1 cKO 4.98 ± 0.16 ms (n = 12)).  
D, At the end of the EAE experiment, the density of oligodendrocytes (CC1+ cells/1,000 µm2) in the spinal cord was not 
different in NR1 cKO mice (control 18.3 ± 0.9 (n = 7) vs NR1 cKO 16.1 ± 1.2 (n = 7). 
 
  
 
 
Figure S6 (Related to Figure 4). Recovery of axon function from OGD decreases with myelination and acute NMDA receptor 
inhibition does not mimic NR1 deficiency 
A-E, After 1 h baseline recording (perfused with oxygenated ACSF) optic nerves are subjected to 60 min OGD and then 
reperfused for a 2 h recovery period with oxygenated ACSF. Functional integrity of axons over time was monitored by 
quantifying the area under the CAPs (evoked by a supramaximal stimulus) and normalizing to baseline. 
A, At P9-10 (when axons are not yet fully myelinated) optic nerves from NR1 cKO showed the same functional decline 
following OGD and recovery thereafter.  
B, At P19-21, myelinated optic nerves from control and NR1 cKO mice exhibited the same rapid loss of conduction, but after 
OGD nerves from NR1 mutants recovered less well. 
C, Following transient OGD optic nerves from adult (fully myelinated) NR1 mutant mice recover less well (-50%) than nerves 
from littermate controls (same image as in Figure 4A).  
D, Incubation of optic nerves from wildtype and NR1 mutants with the NMDA receptor blocker D-AP5 (50 µM, 30 min before 
OGD onset) did not reveal overt differences of the CAP time course and recovery from OGD when compared to control 
conditions (ACSF). Note that NR1 mutants recovered -50% when compared to control nerves, suggesting a largely 
developmental defect. 
E, Optic nerves from controls and NR1 mutants were exposed to transient OGD in Ca2+-free conditions (4 mM Mg2+ 
containing 200 µM EGTA). In the absence of free Ca2+ axonal recovery is improved in both mutants and controls. Note that 
axons from NR1 mutants still recovered less well. 
F, Comparison of functional axon recovery under different experimental conditions. Wildtype optic nerve axons that were 
treated with D-AP5, 7CKA or MK801 to acutely block NMDA receptors revealed comparable recovery to nerves under 
control (ACSF) conditions. Similarly, NR1 mutant optic nerves had equivalent recoveries with or without D-AP5 treatment. 
Under Ca2+ free conditions control optic nerves recovered up to 98 ± 14 % (n = 8) whereas axons from NR1 mutants revealed 
a recovery of 65 ± 6 % (n = 7), P < 0.05 Student t test.  
G, Wildtype optic nerves maintained ex vivo for 16 hours in oxygenated ACSF and treated with either NMDA/ Gly (100 µM), 
or NMDA/ Gly plus 7CKA/ D-AP5 (100 µM) or DMSO (solvent control), were tested for functional integrity and conductivity 
by applying increasing stimulus intensities (0 – 1 mA) in 0.1 mA steps. Depicted are stimulus-response relationships. Nerve 
conduction properties were tested at 2 and 16 hours of incubation for each treatment group. Note that there were no overt 
changes in nerve excitability over 16 hours of treatment, indicating functional integrity of optic nerves (See also Figure 4G). 
 
  
 
 
 
Figure S7 (Related to Figure 6). White matter tracts of brain stem and spinal cord show signs of inflammation  
A, Depicted are longitudinal sections of cerebellum, brainstem and spinal cord (age 10 months), immunostained for activated 
microglia/macrophages (Mac3). In the ventral spinal cord, where the majority of cortico-spinal axons pass, we observed a 
significant increase of this inflammation marker in NR1 mutant mice (see also Figure 6). 
B, C Spinal cord cross-sections from control and NR1 mutant mice stained (B) for astrogliosis (GFAP) and (C) for activated 
microglia/macrophages (Mac3).  
Black boxes mark regions of higher magnifications; scale bars 100 µm (A) and 50 µm (B, C). 
 
  
 
Supplemental Experimental Procedures  
 
Purification of OPCs by immunopanning. 
OPCs utilized for biotinylation assays, for measurements of 2-deoxyglucose uptake or lactate release by NMR were further 
purified to 98.2±0.3% by negative selection immunopanning (Barres et al., 1992). To selectively remove microglia, single cell 
suspensions of mechanically dissociated OPCs were incubated on Petri dishes coated with Bandeiraea simplicifolia (BS) 
lectin1(Cahoy et al., 2008) (2.3μg/ml, Vector labs) for 15 min at 37°C. To selectively remove astrocytes, unattached OPCs and 
astrocytes were then incubated for 30 min at 37°C on dishes sequentially coated with anti-mouse IgG antibody (Jackson 
Immunoresearch) and anti-rat neural antigen-2 (RAN-2) (Bartlett et al., 1981) antibody (i.e. conditioned media from RAN-2 
hybridoma B lymphocytes (ATCC). The remaining purified OPCs were plated and differentiated as described in Experimental 
Procedures. 
 
Glucose sensor FRET imaging  
For glucose sensor confocal imaging, coverslips containing transfected primary oligodendrocytes were transferred to a custom 
made imaging chamber and continuously perfused with ACSF (in mM: NaCl 110.34; KCl 5.33; NaH2PO4 0.906; NaHCO3 
44.05; MgSO4 0.814; CaCl2 1.8; glucose 10; adjusted to pH 7.4 with HCl after equilibration with 5% CO2). The chamber was 
mounted on a Leica SP5 confocal microscope and cells were imaged using a HCX PL APO lambda blue 63x1.20 water-
immersion objective. CFP was excited at 458 nm, and emission filters were set at 470-500 nm and 520-570 nm for detection of 
CFP and YFP fluorescence, respectively. Images were acquired every 10 s. Region of interests were set comprising the soma 
and the major processes of transfected oligodendrocytes. Background corrected mean fluorescence intensities were corrected 
for spectral bleed-through using correction factors obtained by transfecting primary oligodendrocytes with CFP or YFP only 
(Hou et al., 2011). Finally, corrected YFP fluorescence intensity obtained after excitation of CFP (= FRET) was divided by the 
corrected CFP fluorescence and the ratio (Fc/CFP) was normalized to the first 5 min of baseline recording, which was set as 1. 
NMDARs were activated by changing the perfusion solution to ACSF containing 100 µM NMDA and 100 µM glycine. Cells 
were preincubated with the antagonists of NMDA receptors (7CKA, 100 µM; D-AP5, 100 µM) for 30 min before NMDA and 
glycine were applied. For control experiments cells were incubated in ACSF lacking glucose or containing either iodoacetate 
(inhibitor of glycolysis, 1 mM) or cytochalasin B (inhibitor of glucose transpoter, 40 µM). From these data, the Fc/CFP signal 
was calibrated to cytosolic glucose concentrations using the kD = 700 µM of the glucose sensor for glucose as described 
(Bittner et al., 2010). We have continuously monitored the cellular morphology of transfected oligodendrocytes by 
concomitant time lapse imaging to determine that drug applications (e.g. cytochalasin B) did not cause morphological changes 
that influence FRET signals. 
 
 
NMR analysis 
Conditioned media from untreated and 30 min NMDA/Gly (100 µM) treated immunopanned oligodendrocytes were snap 
frozen. Samples were mixed with 10% D2O and the internal standard DSS and transferred to 3 mm NMR tubes. All spectra 
were recorded on an Avance Bruker 700 MHz spectrometer equipped with a cryogenic TXI 1H/13C-15N/2H probe head at 4°C. 
The 13C, 1H-HSQC experiments were done by acquisition of 2048 points in the direct dimension with spectral width of 13 ppm 
and 300 increments in the indirect dimension with spectral width of 95 ppm. The J coupling defocusing delay was set to 4 ms 
(1/21JHC), the recycling time to 1.2 s and the total acquisition time was 3 hours and 46 minutes for each sample. A polynomial 
baseline correction was applied to the time domain signal. The latter was then zero filled to 4096 and 1024 points in the direct 
and indirect dimensions, respectively. Afterwards the time domain data were apodized by multiplication with a cosine function 
set to 0 at t1max and Fourier transformed to the frequency domain in both dimensions. The data processing was performed using 
nmrPipe software (Delaglio et al., 1995). The integrations and quantifications were done using CARA (Keller, 2004). 
 
 
Lactate release by fluorometric measurement of NADH 
Lactate release from cultured oligodendrocytes was analysed as described for astrocytic cultures (Requardt et al., 2010). Mouse 
oligodendrocyte precursor cells were prepared as described above, 50,000 cells were seeded in wells of 24-well cell culture 
plates and were allowed to differentiate for 5 days in SATO medium. Cells were washed once with ACSF containing 10 mM 
glucose, and preincubated in 250 µl of ACSF (control) or ACSF containing 100 µM 7-CKA and/or 100 µM D-AP5 for 30 min. 
Then, cells were incubated in 250 µl ACSF with or without 100 µM NMDA and 100 µM glycine in the presence or absence of 
the inhibitors. For inhibition of glucose transporters, cytochalasin B was added in the concentrations indicated in the figures. 
After 15, 30 and 60 min of incubation 20 µl medium was removed and lactate content was determined using a reaction mixture 
consisting of 0.5 M glutamate buffer pH 8.9, 6 mM NAD+, 35 µg/ml glutamate pyruvate transaminase and 50 µg/ml lactate 
dehydrogenase. After 60 min at 37 °C NADH fluorescence was determined using a plate reader and compared to wells 
containing known concentrations of lactate. Protein determination was done according to the Lowry method using bovine 
serum albumin as a standard. 
 
Immunohistochemistry 
 
Mice were anesthetized (2,2,2-tribromoethanol (2 % v/v) and amyl alcohol (2 % w/v, 0.2 ml/ 10 g body weight) and 
subsequently perfused with 4% paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer. Brains and optic nerves were 
isolated and kept in the same fixative for 8-12 h at 4°C. After washing with PBS, optic nerves were cryoprotected with sucrose 
and frozen in OCT compound (Shandon Cryomatrix, Thermo Scientific) on dry ice. Nerve sections of 12 µm were made on a 
cryostat (Leica, Jung 2045C), mounted on superfrost slides (Superfrost Plus, Thermo Scientific) and air dried at room 
temperature (RT). Slide-mounted sections were washed with PBS and treated with 0.3% Triton X-100 and 5% horse serum for 
1 h at RT. Brain sections of 40 µm were cut coronally with a vibratome (Leica, VT1000S) and treated similarly.  
Primary antibodies were incubated over night at 4°C in 0.3% Triton X-100 and 5% horse serum. Dilutions were as follows: 
GFP (1:800, goat, Rockland; 1:500, rabbit, Abcam), CC1 (1:50, mouse, Calbiochem), Olig2 (1:200, rabbit, gift from C. D. 
Stiles, Boston, MA, USA), NG2 (1:200, rat, gift from J. Trotter, Mainz, Germany), GFAP (1:100, mouse, Novocastra), IBA1 
(1:100, rabbit, Wako), NR1 (1:250, mouse, Zymed Laboratories), MBP (1:300, rabbit, Dako).  
Secondary antibodies to mouse, rabbit and goat conjugated to Alexa 488-(1:2000 Molecular Probes), Alexa-555-(1:2000, 
Molecular Probes), Alexa-633(1:500, Molecular Probes), Cy2-(1:100, Dianova), Cy3-(1:1000, Dianova) and Cy5-(1:500, 
Dianova) were incubated in 2 % horse serum for 2 h at RT. For nuclei labeling DAPI (0.025 µg/ml final concentration) was 
added to the secondary antibody.  
Confocal images were collected with a LSM 510 Meta microscope (Zeiss) using a 20x/0.5 Plan-Neofluar and 40x/1.2 water-
immersion C-Apochromat objective. Excitation was performed at 488 nm, 543 nm and 633 nm, emission was detected for 
Alexa 488/Cy2, Alexa 555/Cy3 and Alexa 633/Cy5 at 500-530 nm band-pass, 560 nm long-pass and 650-710 nm band-pass 
filter sets, respectively. Z-stack images were taken at 0.5 – 1 µm intervals. For reporter analysis confocal stacks of 2-3 different 
sections from 3-4 individual animals were analyzed. For quantification of relative NR1 fluorescence intensities 9-12 confocal 
stacks of 3-4 different longitudinal optic nerve sections of 3 individual animals for each genotype were analyzed. The average 
fluorescence intensity for all stacks was calculated using ImageJ. Data were grouped per animal and normalized to controls.  
 
 
Assessment of genomic recombination 
Real time quantitative PCR (using SYBR Green and a 7500 Fast Real-Time PCR System, Applied Biosystems) was performed 
to amplify a DNA sequence of 184 bp flanking the 5’ loxP site within the 5 kb intron between exons 10 and 11 of the floxed 
NR1 locus. Primers were located closely up- and downstream of the 5’ loxP site and had the following sequence: sense 5’-
GTCAAGCTTAGGATCCGGAACC-3’ and anti-sense 5'-CAACTGCTCTTCCGAAGGTC-3'. Only non-recombined alleles 
would be amplified whereas after successful recombination the anti-sense primer could not anneal to its complementary strand 
impeding the PCR amplification. Genomic DNA was isolated from optic nerves of individual animals. For each sample four 
technical replicates per PCR were implemented. Neuregulin 1 type III (NrgIII) (sense 5'-GTGTGCGGAGA-
AGGAGAAAACT-3' and anti-sense 5'-AGGCACAGAGAGGAATTCATTTCTTA-3') and Gria1 (sense 5'-CCAGGTGTCTT-
CTCCTTTCTTG-3' and anti-sense 5'-CTGAAACGGCTGACCAGG-3') were used as endogenous gene controls. Data 
normalization and analysis were performed with the 7500 Fast System Software. This approach enabled a relative 
quantification of the extent of recombined alleles in the optic nerves of NR1 cKO mice. 
 
 
Electron microscopy 
Following tissue preparation and fixation, samples were dehydrated in a graded series of ethanol, and then embedded in Epon. 
For HPF freshly dissected optic nerves were placed in an aluminum specimen carrier with a 0.1 mm or 0.2 mm indentation 
(Microscopy Services, Kiel, Germany). Remaining space was covered with yeast paste or 20% PVP in PBS, and the sample 
was cryofixed in a Bal-Tec HPM010 high-pressure freezer (former Bal-Tec, now ABRA-Fluid AG, Widnau, Switzerland). 
Freeze-substitution was carried out in a Leica AFS (Leica, Vienna, Austria) as follows: Samples were first kept in tannic acid 
(Sigma-Aldrich) 0.1% in acetone at −90°C for 100 h, washed with acetone (4 x 30 min, −90°C), and then transferred into OsO4 
(Science Services, Munich, Germany) 2 % in acetone, −90°C. The temperature was raised from −90°C to −20°C in increments 
of 5°C/h, then kept unaltered at −20°C for 16 h, and then raised from −20°C to +4°C in increments of 10°C/h. Then the 
samples were washed with acetone (3 x 60 min at 4°C), allowed to adjust to room temperature (1 h), and finally transferred 
into Epon (Serva) (50% Epon in acetone for 3 h, 90% Epon in acetone for 18 h, 100% Epon for 6 h). The samples were placed 
in an embedding mold and polymerized (60°C, 24 h). Ultrathin sections (50 nm) were cut using a Leica Ultracut S 
ultramicrotome (Leica, Vienna, Austria) and stained with an aqueous solution of 2% uranyl acetate (Merck, Darmstadt, 
Germany) followed by lead citrate (Reynolds, 1963). 
 
Optic nerve recordings analysis 
 
Acutely isolated optic nerves were stimulated and recorded from by custom-made suction electrodes back-filled with ACSF 
[(in mM): 124 NaCl, 3.0 KCl, 2.0 CaCl2, 2.0 MgSO4, 1.25 NaH2PO4, 23 NaHCO3, and 10 glucose]. The stimulation electrode 
was connected to a stimulus isolator (385, WPI) to evoke compound action potentials (CAP). The recording electrode was 
connected to a Heka amplifier (EPC9), and the signal was amplified 500 times, filtered at 30 kHz, and acquired at 20-30 kHz. 
Before recording, optic nerves were equilibrated for at least 15 min in the chamber. Square-wave constant current stimulus 
pulse (50 µs) strength was adjusted to evoke the maximum CAP possible, and then increased an additional 25 % for 
supramaximal stimulation. 
 
Stimulus-response relationships were performed by varying stimulus intensity from 0.1 to 1 mA and measuring the area of the 
corresponding graded CAPs. This protocol allowed for comparison of the relative thresholds of activation of the population of 
conducting fibers. The CAP area was expressed as percentage of the last CAP area (at maximum stimulation of 1 mA) in the 
train.  
The CAP latency was measured (at supramaximal stimulation after averaging 50 CAPs elicited every 30 s) as the time between 
the onset of the stimulus artefact to the first, second and third peak as previously described (Baltan et al., 2010). The suction 
electrode recording configuration at supramaximal stimulation allows all axons in optic nerves to be activated and the resultant 
action potential from each axon to be recorded. This method has the advantage of enabling stable recording of three-peaked 
characteristic shape of CAPs. These peaks reflect three sub-groups of axon populations based on their conduction velocity and 
the area under the CAP reflecting the number of contributing axons (Cummins et al., 1979). 
 
For pharmacology of OGD recordings the following experiments were performed. A Ca2+-free ACSF was used in some 
experiments and contained 200 µM EGTA and 4 mM Mg2+ (to maintain constant divalent cation concentration). Control 
experiments indicated that CAPs remained essentially unchanged in this solution (with normal glucose and oxygen) for at least 
90 min. 7-chlorokynurenic acid (7-CKA, 50 µM; dissolved in DMSO as 50 mM stock), D-(-)-2-Amino-5-phosphonopentanoic 
acid (D-AP5, 100 µM) and MK801 (50 µM, dissolved in DMSO as 50 mM stock ) were used to block NMDA receptors during 
recordings. Optic nerves treated with pharmacological substances or Ca2+-free ACSF were incubated 30 min before, during and 
30 min after OGD. 
 
 
Surgery for in vivo spinal cord CAP recordings 
Surgery for in vivo spinal cord recordings was slightly modified as previously described (Dibaj et al., 2012; Steffens et al., 
2012). Anaesthesia was initiated by 80 mg/kg pentobarbital injected i. p. After cannulation of the jugular vein, anesthesia was 
continued with 40-60 mg methohexital per kg and h. A tracheotomy was performed and a tube inserted for artificial 
ventilation. Active respiratory movements were abolished by paralysis with pancuronium (800 µg per kg supplemented i.p. 
every hour) and artificial ventilation with a gas mixture of CO2 (2.5 %), O2 (47.5 %), and N2 (50 %) at 120 strokes/min (100-
160 µl/stroke depending on the body weight) was performed. Body temperature, heart rate and O2 blood saturation were 
continuously monitored and also used to control the level of anesthesia. The vertebral column was rigidly fixed with two 
custom-made clamps. A laminectomy was performed from vertebrae TH13 to L5 to expose the spinal cord segments L1 to L4 
as well as to expose the dorsal roots L3 to L5. For electrophysiology, the spinal cord was covered with mineral oil.  
 
 
Behavioural assessment of visual acuity and contrast sensitivity 
Visual acuity and contrast sensitivity response were assessed using the virtual-reality optomotor system (Douglas et al., 2005; 
Prusky et al., 2004). In the optomotor system freely moving animals were exposed to moving sine wave gratings of various 
spatial frequencies, contrasts and drift speeds and reflexively tracked this pattern by head movements as long as they could see 
it. Experimenters were blind to the animal’s genotype and thresholds were regularly validated independently by more than one 
observer. 
 
Experimental autoimmune encephalomyelitis (EAE) induction 
EAE experiments were carried out in 8-12 week-old mice as described earlier (Matute et al., 2007). Briefly, chronic, relapsing 
EAE was induced in littermate control and in NR1 cKO mice, by immunization with 300 µl of myelin oligodendrocytes 
glycoprotein 35–55 [MOG(35–55)] (200 µg; Sigma) in incomplete Freund’s adjuvant supplemented with 8 mg/ml 
Mycobacterium tuberculosis H37Ra. Pertussis toxin (500 ng; Sigma) was injected intraperitoneally on the day of immunization 
and again 2 d later. In all instances, motor symptoms were recorded daily and scored as follows from 0 to 8: 0, no detectable 
changes in muscle tone and motor behaviour; 1, flaccid tail; 2, paralyzed tail; 3, impairment or loss of muscle tone in hind 
limbs; 4, hind limb hemi-paralysis; 5, complete hind limb paralysis; 6, complete hind limb paralysis and loss of muscle tone in 
forelimbs; 7, tetraplegia; and 8, moribund. Conduction velocity of the corticospinal tract was assessed in anesthetized mice 
with tribromoethanol (240 mg/kg, i.p.; Sigma) using stimulatory and recording electrodes placed in the primary motor cortex 
and in the vertebral canal at the L2 level, respectively. After recording, mice were fixed, and spinal cord was processed for 
immunohistochemistry. Tissue blocks of spinal cords were cryoprotected, cut longitudinally (10 µm thick), and stained with 
toluidine blue and antibody to CC1 (1 µg/ml; Calbiochem, Barcelona, Spain). 
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